Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
56
datasets available to search
ShareScore release 0.9.0
Dataset results
56 results for “remdesivir”
A Competing Compound For Remdesivir and Molnupiravir In Inhibiting RdRp Protein of COVID-19
<p>According to a docking study conducted with the online tool [1][2], the compound Nicotinate mononucleotide with the formula C11H15NO9P+ could inhibit RNA-dependent RNA polymerase (RdRp (RTP site)) protein in COVID-19 coronavirus, with a Score Value of -9.4 (kcal / mol). This is better than the amount for the Remdesivir molecule (-9.2 (kcal / mol)) and after MW correction, it is also better than Molnupiravir, to inhibit the same protein. Since inhibition of this protein plays a key role in the inhibitory function of Remdesivir against COVID-19 virus [3], we can see the Nicotinate mononucleotide compound as an alternative to Remdesivir in inhibiting this coronavirus. Since the molecular weight of Nicotinate mononucleotide (336 g / mol) is approximately half that of Remdesivir (603 g / mol) and Molnupiravir-active-form (499.16 g / mol), it is better in terms of both protein adhesion and absorption capacity. Since the main precursor of Nicotinate mononucleotide, Trigonelline alkaloid, is a naturally occurring plant secondary metabolite, and Nicotinate mononucleotide itself is present in mammalian biomolecular pathways, it is likely to be more available, more cost-effective, and more non-toxic and be better than Remdesivir and Molnupiravir. Please see added data.</p>
PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
ClinicalTrials.gov study NCT04582266. IPD Sharing: YES. Countries: 1. Publications: 1.
Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials
<p><strong>Background</strong>: To summarize specific adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir in patients with COVID-19.</p> <p><strong>Methods</strong>: We searched 32 databases through 27 October 2020. We included randomized trials comparing any of the drugs of interest to placebo or standard care, or against each other. We conducted fixed-effects pairwise meta-analysis and assessed the certainty of evidence using the GRADE approach.</p> <p><strong>Results</strong>: We included 16 randomized trials which enrolled 8226 patients. For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty. Compared to standard care or placebo, low certainty evidence suggests that remdesivir may not have an important effect on acute kidney injury or cognitive dysfunction/delirium. Low certainty evidence suggests that hydroxychloroquine may increase the risk of cardiac toxicity (and cognitive dysfunction/delirium, whereas moderate certainty evidence suggests hydroxychloroquine probably increases the risk of diarrhoea (RD 106 more per 1000, 95% CI: 48 more to 175 more) and nausea and/or vomiting (RD 62 more per 1000, 95% CI: 23 more to 110 more) compared to standard care or placebo. Low certainty evidence suggests lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting compared to standard care or placebo.</p> <p><strong>Discussion</strong>: Hydroxychloroquine probably increases the risk of diarrhoea and nausea and/or vomiting and may increase the risk of cardiac toxicity and cognitive dysfunction/delirium. Lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting. Remdesivir may have no important effect on risk of acute kidney injury or cognitive dysfunction/delirium. These findings provide important information to support the development of evidence-based management strategies for patients with COVID-19.</p> <p><strong>Funding</strong>: This study was supported by the Canadian Institutes of Health Research (grant: VR4-172738)</p> <p><strong>Registration</strong>: Not registered in PROSPERO, protocol available in the supplementary material of BMJ 2020;370:m2980; http://dx.doi.org/10.1136/bmj.m2980.</p>
Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19
<p>Updated Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19.</p>
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
ClinicalTrials.gov study NCT04292730. IPD Sharing: YES. Countries: 15. Publications: 3.
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
ClinicalTrials.gov study NCT04847622. IPD Sharing: NO. Countries: 5. Publications: 1.
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
ClinicalTrials.gov study NCT04745351. IPD Sharing: YES. Countries: 6. Publications: 2.
IFN-beta 1b and Remdesivir for COVID19
ClinicalTrials.gov study NCT04647695. IPD Sharing: YES. Countries: 1. Publications: 8.
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
ClinicalTrials.gov study NCT04501952. IPD Sharing: YES. Countries: 4. Publications: 4.
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
ClinicalTrials.gov study NCT04292899. IPD Sharing: YES. Countries: 15. Publications: 4.
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
ClinicalTrials.gov study NCT05502081. IPD Sharing: YES. Countries: 1. Publications: 10.
Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials
Open the record for dataset details and reuse information.
Screening of 67 compounds with predicted biosignature profile similar to remdesivir for anti-SARS-CoV-2 activity
<p>This short report describes the most relevant results of screening compounds with a similar predicted biosignature as remdesivir in a VeroE6 cell-based anti-SARS-CoV-2 assay.</p>
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
ClinicalTrials.gov study NCT04385719. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
ClinicalTrials.gov study NCT04596839. IPD Sharing: NO. Countries: 1. Publications: 17.
A Trial of Remdesivir in Adults With Severe COVID-19
ClinicalTrials.gov study NCT04257656. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
ClinicalTrials.gov study NCT05911906. IPD Sharing: YES. Countries: 1. Publications: 0.
Remdesivir in COVID-19 Lahore General Hospital
ClinicalTrials.gov study NCT04560231. IPD Sharing: NO. Countries: 1. Publications: 3.
SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)
ClinicalTrials.gov study NCT04978259. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
ClinicalTrials.gov study NCT04252664. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.